HT
APLT

Headlands Technologies’s Applied Therapeutics APLT Stock Holding History

Headlands Technologies’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23
Closed -$20 – 1128
2024
Q4 		$20 Buy
+23
New +$144 ﹤0.01% 1158

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Headlands Technologies's APLT Position: Q1 2025 in Review

Headlands Technologies sold out of Applied Therapeutics (APLT) in Q1 2025, closing a stake of 23 shares — an estimated $20 sold.

Headlands Technologies first reported a position in APLT in Q4 2024 and held it in 1 quarter. The position peaked at $20 in Q4 2024. 90 funds tracked by Wall St. Rank hold APLT as of Q1 2025.

  • Headlands Technologies reported no remaining Applied Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Headlands Technologies sold 23 Applied Therapeutics shares in Q1 2025, an estimated $20.
  • Headlands Technologies first reported a position in Applied Therapeutics in Q4 2024 and held it in 1 quarter.
  • Headlands Technologies's Applied Therapeutics position peaked at $20 in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2025.

Based on Headlands Technologies's 13F filing for Q1 2025, filed 9 May 2025.